Advanced therapies in patients with congenital heart disease-related pulmonary arterial hypertension: results from a long-term, single center, real-world follow-up

详细信息    查看全文

• 作者：Silvia Favilli ; Gaia Spaziani ; Piercarlo Ballo…
• 关键词：Pulmonary arterial hypertension ; Congenital heart disease ; Advanced therapy ; Eisenmenger syndrome
• 刊名：Internal and Emergency Medicine
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：10
• 期：4
• 页码：445-450
• 全文大小：523 KB
• 参考文献：1.Engelfriet PM, Duffels MG, M?ller T, Boersma E, Tijssen JG, Thaulow E, Gatzoulis MA, Mulder BJ (2007) Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 93:682-87PubMed Central PubMed View Article
  2.Van de Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, Vachiéry JL, Paelinck B, Morissens M, Budts W (2009) The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol 64:447-53PubMed View Article
  3.Borghi A, Ciuffreda M, Quattrociocchi M, Preda L (2007) The grown-up congenital cardiac patient. J Cardiovasc Med 8:78-2View Article
  4.Mulder BJ (2010) Changing demographics of pulmonary arterial hypertension in congenital heart disease. Eur Resp Rev 19:308-13View Article
  5.Diller GP, Dimopoulos K, Broberg CS, Kaya MG, Naghotra US, Uebing A, Harries C, Goktekin O, Gibbs JS, Gatzoulis MA (2006) Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 27:1737-742PubMed View Article
  6.Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S, Eisenmenger sindrome (1998) Factors relating to deterioration and death. Eur Heart J 19:1845-855PubMed View Article
  7.Diller GP, Gatzoulis MA (2007) Pulmonary vascular disease in adults with congenital heart disease. Circulation 115:1039-050PubMed View Article
  8.Dimopoulos K, Inuzuka R, Goletto S et al (2010) Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121:20-5PubMed View Article
  9.D’Alto M, Diller GP (2014) Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart May 14 [Epub ahead of print]
  10.Beghetti M, Galiè N (2009) Eisenmenger syndrome. A clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 53:733-40PubMed View Article
  11.Diller GP, Alonso-Gonzalez R, Dimopoulos K, Alvarez-Barredo M, Koo C, Kempny A, Harries C, Parfitt L, Uebing AS, Swan L, Marino PS, Wort SJ, Gatzoulis MA (2012) Disease targeting therapies with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol 167:840-47PubMed View Article
  12.Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG) (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-537PubMed View Article
  13.Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O’Fallon WM, Pieroni DR, Wolfe RR, Weidman WH (1993) Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 87:I38–I51PubMed View Article
  14.Duffels MG, Engelfriet PM, Berger RM, van Loon RL, Hoendermis E, Vriend JW, van der Velde ET, Bresser P, Mulder BJ (2007) Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 120:198-04PubMed View Article
  15.Favilli S, Santoro G, Ballo P, Arcangeli C, Bovenzi FM, Chiappa E, Conti U, Monopoli A, Murzi B, Rosini C, Zuppiroli A (2012) Prevalence and clinical characteristics of adult patients with congenital heart disease in Tuscany. J Cardiovasc Med 13:805-09View Article
  16.Diller GP, Kempny A, Inuzuka R, Radkr R, Wort SJ, Baumgartner H, Gatzoulis M, Dimopoulos K (2014) Survival prospects of treatment na?ve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart 100:1366-372PubMed View Article
  17.Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, Landzberg MJ (2003) Usefulness of epoprostenol therapy in the severely ill adolescents/adults with Eisenmenger physiology. Am J Cardiol 91:632-35PubMed View Article
  18.Baumgartner H, Bonhoeffer P, De Groot N et al (2010) ESC guidelines for the management of grown-up congenital heart disease. Eur Heart J 31:2915-957PubMed View Article
  19.D’Alto M, Mahadevan VS (2012) Pulmonary arterial hypertension associated with congenital heart disease. Eur Resp Rev 21:328-37View Article
  20.Beghetti M, Galiè N, Bonnet D (2012) Can “inoperable-congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis 21:3-1View Article
  21.Hawkins A, Langton-Hewer S, Henderson J, Tulloh RM (2011) Management
• 作者单位：Silvia Favilli (1)
  Gaia Spaziani (1)
  Piercarlo Ballo (2)
  Veronica Fibbi (1)
  Gennaro Santoro (3)
  Enrico Chiappa (1)
  Chiara Arcangeli (3)
  
  1. Pediatric Cardiology, Meyer Hospital, Viale Pieraccini 24, 50134, Florence, Italy
  2. Cardiology Unit, S. Maria Annunziata Hospital, Via dell’Antella 58, 50012, Florence, Italy
  3. Cardiology Unit, Careggi Hospital, Largo Brambilla 3, 50100, Florence, Italy
  
• 刊物主题：Internal Medicine;
• 出版者：Springer Milan
• ISSN：1970-9366

文摘

Pulmonary arterial hypertension (PAH) is a common finding in patients with congenital heart disease (CHD), and has relevant prognostic implications. The recent introduction of advanced therapies (AT) considerably improved the clinical outcome of these patients, but real-world data are still lacking. We aimed at reporting the results of a long-term follow-up of CHD patients with PAH undergoing AT, followed at a tertiary Center during the two last decades. The study population included a total of 34 patients with an established diagnosis of CHD-related PAH. In addition to conventional treatment, 97?% of patients started AT during the follow-up. Over a median follow-up of 9 [3-1] years, 11 (32.4?%) patients died: 7 of them were affected by Eisenmenger syndrome and the majority of patients were in NYHA class ? at the time of death. Among the 23 patients who were alive at the last follow-up, the majority were in NYHA class I-II. Oxygen saturation and 6-min walking distance improved in all subjects within the first 6?months after starting of AT. One patient with ventricular septum defect and high pulmonary resistances was successfully treated with AT to lower resistances and underwent defect closure. A good clinical outcome was also observed in the subset (n?=?8) with Down syndrome. The results of this real-world experience suggest that, despite a relatively high mortality rate mostly related to late commencement of AT, the clinical outcome of subjects with CHD-related PAH undergoing AT are characterized by a good quality of life and clinical improvement in most patients.